Project Description

9Meters
Making Celiac Disease, And Dietary Restrictions, a Thing of the Past

Date & Time:

October 20, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

More than 3 million people in the U.S. suffer from celiac disease, making it more common than ulcerative colitis, Crohn’s disease, and rheumatoid arthritis. Unfortunately, the only current treatment for celiac is a gluten free diet. It’s an area that Dr. Alessio Fasano knows a great deal about. As a leading gastroenterologist, Dr. Fasano directs the Center for Celiac Research at Mass General and a visiting professor at Harvard Medical School, specializing in the treatment of patients of all ages with gluten-related disorders, including celiac disease, wheat allergy and gluten sensitivity.

9 Meters BioPharma (NASDAQ: NMTR) is a development stage company that focuses on rare and unmet needs in digestive diseases and unique GastroIntestinal (GI) biology. Their lead candidate, Lazarotide, is the first drug to move into a Phase 3 trial in celiac. The study will be completed in 2022 and has been given fast-track designation by the FDA.

9 Meters also has 4 other programs in their pipeline including a Phase 2 trial of a treatment for Short Bowel Syndrome, a debilitating condition related to poor absorption of nutrients as a result of at least half of the small intestine being removed due to accident or illness.

Join our webinar to hear from 9 Meters President and CEO, Dr. John Temperato and Dr. Alessio Fasano about Lazarotide and the four other GI therapies the company has in its pipeline.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.